SCHEMBL976147

SCHEMBL976147

c1ccc(-c2nnnn2C(c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 5/20 0.45
TSHR P16473 3/20 0.45
KMT2A Q03164 1/20 0.44
POLB P06746 2/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
PTGS2 P35354 2/20 0.42
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
P2RX7 Q99572 2/20 0.39
HSD11B1 P28845 1/20 0.39
ALOX15 P16050 1/20 0.38
AGTR1 P30556 1/20 0.38
AGTR2 P50052 1/20 0.38
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9235857 0.90 MEN1 (0.42) LMNAHSD17B10ALDH1A1TSHRKMT2A
SCHEMBL9025603 0.89 MEN1 (0.41) LMNAHSD17B10ALDH1A1TSHRKMT2A
SCHEMBL8323797 0.89 LMNA (0.39) LMNAHSD17B10ALDH1A1TSHRKMT2A
SCHEMBL8698703 0.88 AGTR1 (0.47) LMNAHSD17B10ALDH1A1TSHRKMT2A
SCHEMBL9025749 0.85 AGTR1 (0.43) LMNAHSD17B10ALDH1A1TSHRKMT2A
SCHEMBL7195878 0.85 LMNA (0.43) LMNAALDH1A1POLBHTTL3MBTL1
SCHEMBL3256000 0.85 CA1 (0.43) LMNAHSD17B10ALDH1A1TSHRPOLB
SCHEMBL7196989 0.85 AGTR1 (0.41) LMNAHSD17B10ALDH1A1TSHRPOLB
SCHEMBL7611179 0.85 MAOA (0.43) LMNAHSD17B10ALDH1A1TSHRKMT2A
SCHEMBL27347057 0.85 LMNA (0.36) LMNAHSD17B10ALDH1A1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189457-A1 Novel synthesis of irbesartan TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-05-26 EP claimed
US-20090216026-A1 Novel synthesis of irbesartan NISNEVICH GENNADY 2009-08-27 US claimed
EP-2039693-A2 Novel synthesis of irbesartan Teva Pharmaceutical Industries Limited (IL) 2009-03-25 EP claimed
EP-1931648-A2 PROCESSES FOR THE SYNTHESIS OF 5-PHENYL -1 TRITYL-1H-TETRAZOLE Teva Pharmaceutical Industries Ltd. (IL) 2008-06-18 EP claimed
US-20080103312-A1 Processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole TEVA PHARMACEUTICALS USA, INC. 2008-05-01 US claimed
WO-2008027385-A2 PROCESSES FOR THE SYNTHESIS OF 5-PHENYL -1 TRITYL-1H-TETRAZOLE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-03-06 WO claimed
CN-1759113-A Novel synthesis method of irbesartan TEVA PHARMA (IL) 2006-04-12 CN claimed
US-20040192713-A1 Novel synthesis of irbesartan TEVA PHARMACEUTICALS USA, INC. 2004-09-30 US claimed
US-10300471-B2 Ruthenium-catalyzed synthesis of biaryl compounds in water CHICAGO DISCOVERY SOLUTIONS, LLC 2019-05-28 US disclosed
US-20160263565-A1 RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER CHICAGO DISCOVERY SOLUTIONS, LLC (US) 2016-09-15 US disclosed
US-20160263565-A1 RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER CHICAGO DISCOVERY SOLUTIONS, LLC (US) 2016-09-15 US disclosed
US-9216970-B2 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-12-22 US disclosed
US-9216970-B2 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-12-22 US disclosed
US-9216970-B2 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-12-22 US disclosed
EP-0846117-A1 PROCESS FOR PREPARATION OF BIPHENYL DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1998-06-10 EP disclosed
US-5760220-A REACTING PROTECTED TETRAZOLYLPHENYL ZINC HALIDE WITH HALOPHENYLMETHYL PYRIDO/2,3-D/PYRIMIDONE IN PRESENCE OF PALLADIUM OR NICKEL CATALYST AMERICAN HOME PRODUCTS CORPORATION (US) 1998-06-02 US disclosed
EP-0782996-A1 PROCESS FOR PRODUCING N-BIPHENYLMETHYLTHIADIAZOLINE DERIVATIVE OR SALT THEREOF AND INTERMEDIATE FOR PRODUCING THE SAME WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1997-07-09 EP disclosed
WO-1996040684-A1 PROCESS FOR PREPARATION OF BIPHENYL DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1996-12-19 WO disclosed
US-5310929-A Hypotensive E. I. DU PONT DE NEMOURS AND COMPANY (US) 1994-05-10 US disclosed
WO-1994003435-A1 PRODRUGS OF IMIDAZOLE CARBOXYLIC ACIDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103312-A1 Processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole REN, AGTR1, AGTR2 LMNA 2439/4885HSD17B10 3027/4885ALDH1A1 897/4885
US-10300471-B2 Ruthenium-catalyzed synthesis of biaryl compounds in water RUVBL2, RUVBL1, CYP2W1 LMNA 3074/4885HSD17B10 1122/4885ALDH1A1 2208/4885
US-20040192713-A1 Novel synthesis of irbesartan REN, AGTR1, AGTR2 LMNA 3493/4885HSD17B10 1326/4885ALDH1A1 1102/4885
US-20090216026-A1 Novel synthesis of irbesartan AGTR1, REN, AGTR2 LMNA 3976/4885HSD17B10 2255/4885ALDH1A1 731/4885
US-20160263565-A1 RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER RUVBL2, RUVBL1, CYP2W1 LMNA 3074/4885HSD17B10 1122/4885ALDH1A1 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.